Investigational Epcoritamab (DuoBody CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
Media ReleaseCOPENHAGEN, Denmark; December 8, 2024 Preliminary analyses from the EPCORE® CLL-1…
Leading AI-driven Skin Analysis Provider EveLab Insight Partners with Dr. Idriss for Series of Retail Activations
SINGAPORE, Dec. 05, 2024 (GLOBE NEWSWIRE) -- EveLab Insight, a leading provider…
Xinhua Silk Road: Annual analysis report on taro price index released at the 2024 Boao Forum for Entrepreneurs
BEIJING, Dec. 5, 2024 /PRNewswire/ -- The annual analysis report on the…
Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban
November 16, 2024 16:38 ET | Source: Anthos Therapeutics Data presented at…